Our Pipeline

Our goal is to transform the prevention and treatment of cancers and infectious diseases to significantly improve the lives of patients by developing and commercializing a new class of immunotherapeutics.

We are leveraging our modular arenavirus platform to develop the following product candidates for multiple cancers and infectious diseases - the efficacy of our replicating and non-replicating platforms is being tested all across our pipeline:

(1) ClinicalTrials.gov: NCT04180215; (2) ClinicalTrials.gov: NCT03629080